- Home
- PIRS vs KZIA Comparison
PIRS vs KZIA Comparison
Compare PIRS & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PIRS
- KZIA
- Stock Information
- Founded
- PIRS 2001
- KZIA 1994
- Country
- PIRS United States
- KZIA Australia
- Employees
- PIRS N/A
- KZIA N/A
- Industry
- PIRS Biotechnology: Pharmaceutical Preparations
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- PIRS Health Care
- KZIA Health Care
- Exchange
- PIRS Nasdaq
- KZIA Nasdaq
- Market Cap
- PIRS 22.4M
- KZIA 18.7M
- IPO Year
- PIRS N/A
- KZIA 1999
- Fundamental
- Price
- PIRS $15.93
- KZIA $5.61
- Analyst Decision
- PIRS
- KZIA Strong Buy
- Analyst Count
- PIRS 0
- KZIA 1
- Target Price
- PIRS N/A
- KZIA $20.00
- AVG Volume (30 Days)
- PIRS 37.6K
- KZIA 123.2K
- Earning Date
- PIRS 11-13-2024
- KZIA 11-29-2024
- Dividend Yield
- PIRS N/A
- KZIA N/A
- EPS Growth
- PIRS N/A
- KZIA N/A
- EPS
- PIRS N/A
- KZIA N/A
- Revenue
- PIRS $1,352,000.00
- KZIA $1,663,331.00
- Revenue This Year
- PIRS N/A
- KZIA $802.53
- Revenue Next Year
- PIRS N/A
- KZIA N/A
- P/E Ratio
- PIRS N/A
- KZIA N/A
- Revenue Growth
- PIRS N/A
- KZIA 10739.13
- 52 Week Low
- PIRS $6.20
- KZIA $1.90
- 52 Week High
- PIRS $22.32
- KZIA $15.80
- Technical
- Relative Strength Index (RSI)
- PIRS 43.29
- KZIA 52.19
- Support Level
- PIRS $15.15
- KZIA $4.30
- Resistance Level
- PIRS $16.97
- KZIA $6.01
- Average True Range (ATR)
- PIRS 0.72
- KZIA 0.88
- MACD
- PIRS -0.08
- KZIA -0.11
- Stochastic Oscillator
- PIRS 30.75
- KZIA 37.18
About PIRS Pieris Pharmaceuticals Inc.
Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of the Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store, and transport a wide spectrum of molecules. The Company's clinical pipeline consists of immuno-oncology, or IO, bispecifics in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Geographically, all the operations of the firm function through the region of the United States.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.